Last reviewed · How we verify
MMF Immunosuppression
Inhibits inosine monophosphate dehydrogenase (IMPDH)
Inhibits inosine monophosphate dehydrogenase (IMPDH) Used for Prevention of organ rejection in kidney transplant patients.
At a glance
| Generic name | MMF Immunosuppression |
|---|---|
| Also known as | RITUXIMAB |
| Sponsor | Wondercel Biotech (ShenZhen) |
| Drug class | Immunosuppressant |
| Target | IMPDH |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
MMF works by inhibiting the enzyme inosine monophosphate dehydrogenase (IMPDH), which is involved in the synthesis of guanine nucleotides. This leads to a decrease in the proliferation of T and B lymphocytes.
Approved indications
- Prevention of organ rejection in kidney transplant patients
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Abdominal pain
Key clinical trials
- Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies (PHASE2)
- Tocilizumab in Lung Transplantation (PHASE2)
- Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (PHASE4)
- US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies (PHASE1, PHASE2)
- Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD
- US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia (PHASE2)
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MMF Immunosuppression CI brief — competitive landscape report
- MMF Immunosuppression updates RSS · CI watch RSS
- Wondercel Biotech (ShenZhen) portfolio CI